Institution Directory

Clinical trials at University of Alabama at Birmingham

Sites in Birmingham, AL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 7:34 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1239

Shown on this page

Current sort

Live official records

Conditions: Advanced Solid Tumor
Interventions: AI-081; Drug
Lead sponsor: OncoC4, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Birmingham, Alabama • Springdale, Arkansas • Washington D.C., District of Columbia + 18 more

Conditions: Sepsis, Length of Stay, Mortality, Neurodevelopmental Delay
Interventions: Limited Trophic Feeds (1 day of trophic feeds), Extended Trophic Feeds (3 days of trophics); Other
Lead sponsor: University of Washington; Other
Eligibility: 0 Years to 2 Years
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 6
States / cities: Birmingham, Alabama • Tampa, Florida • Oklahoma City, Oklahoma + 3 more

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions: Carboplatin, Cisplatin, Computed Tomography, Durvalumab, Etoposide, Image Guided Radiation Therapy, Nab-paclitaxel, Osimertinib, Paclitaxel, Pemetrexed, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy; Drug · Procedure · Biological + 2 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 476
States / cities: Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 357 more

Conditions: Incontinence, Prolapse
Interventions: Telehealth intervention; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 357 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Astegolimab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 68
States / cities: Birmingham, Alabama • Dothan, Alabama • Jasper, Alabama + 56 more

Conditions: Stroke Hemorrhagic
Interventions: Surgical management, Medical Management; Procedure · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 19 more

Conditions: Family Caregivers, Distress in Caregivers of Cancer Patients, Advanced Cancer
Interventions: FamilyStrong; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Moderate Traumatic Brain Injury (TBI), Severe Traumatic Brain Injury
Interventions: Valproic Acid (VPA), Standard of care treatment + normal saline; Drug · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 8
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 5 more

Conditions: Glioblastoma, Glioblastoma (GBM), Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Gliosarcoma, Adult, Gliosarcoma of Brain
Interventions: C134; Drug
Lead sponsor: James Markert, MD; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Myeloproliferative Neoplasms
Interventions: INCB160058, Standard disease-directed therapy; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 13
States / cities: Birmingham, Alabama • Palo Alto, California • Tampa, Florida + 8 more

Conditions: Neuroblastoma
Interventions: Naxitamab; Drug
Lead sponsor: Giselle Sholler; Other
Eligibility: 12 Months to 21 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2036
U.S. locations: 21
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 18 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 40 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

About this University of Alabama at Birmingham institution page

What this page lists: ClinicalTrials.gov records that list University of Alabama at Birmingham in Birmingham, AL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at University of Alabama at Birmingham

Filter and sort this campus

Live official records

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

Limited Versus Extended Trophic Feeding (LET-FEED) Trial

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

A Telehealth Intervention to Increase Patient Preparedness for Surgery in Latinas

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Rapid Evacuation and Access of Cerebral Hemorrhage Trial

The FamilyStrong Pilot Randomized Trial

Valproic AcId for Traumatic BRAin INjury Trial

A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

About this University of Alabama at Birmingham institution page